Buy a domestic vaccine
Russian scientists will develop a vaccine against alcoholism
Alexander Abramov, "Medvestnik"
Today, there are two main groups of anti-alcohol drugs on the market: those that cause alcohol intolerance and those that reduce the craving for alcohol. At the same time, they either have a low duration of action, or are characterized by high cost and require medical supervision.
The vaccine developed by Russian scientists refers to drugs that reduce the craving for alcohol. The drug works by the method of inverse immunomodulation. The essence is to increase the number of antibodies to the enzyme (alcohol dehydrogenase, ADH), which is responsible for the processing of alcohol, and the restoration of the neurotransmitter exchange system (serotonin, dopamine) - intermediaries of the brain involved in the transmission of information from neuron to neuron. With the introduction of the developed vaccine in the blood serum, the excess activity of enzymes (ADH) decreases, which allows balancing and restoring the exchange of neurotransmitters, reducing alcohol dependence.
According to Maxim Lovat, Ph.D., an employee of the Department of Physiology of the MSU Biofactory, head of the vivarium-experimental complex of the MSU Mitoengineering Research Institute, there is no drug in the world that works according to a similar algorithm. It is expected that the domestic vaccine will have a long-term anti-alcohol effect and a low price, which is due to the low cost of components and the ease of vaccination, reports RVC.
The efficiency of the prototype of the anti-alcohol vaccine has already been demonstrated in laboratory animal studies. Scientists have completed the first stage of preclinical trials and optimized the composition of the vaccine, confirming its effectiveness in suppressing the desire to take alcohol in rats. As the next stage, preclinical trials are planned to test non-standard reactions to the introduction of the vaccine and the safety of the drug. According to the results of the first conducted studies, no side effects were found.
In the near future, the developers will conduct a full range of R&D and preclinical research on the basis of the vivarium-experimental complex of the Research Institute of Mitoengineering of Moscow State University. After that, they plan to sell licenses for the production of the vaccine to large pharmaceutical companies. The vaccine project has already received a grant under the Start program from the Innovation Assistance Fund, a positive conclusion on the status of a resident of the Skolkovo Foundation and positive feedback from representatives of the pharmaceutical industry at industry events.
According to GBI Research, the market volume of drugs aimed at the treatment of pathological addictions (analysis of data for the USA, Great Britain, Germany, France, Italy, Spain, Japan) will amount to 12.7 billion US dollars by 2018.
Portal "Eternal youth" http://vechnayamolodost.ru
28.12.2016